Biogen Inc. expects gradual uptake of its new Alzheimer’s disease drug in the U.S. and said it would consider adjusting its $56,000-a-year price if the medication is taken by more patients than anticipated.
Trending:
Biogen expects slow Alzheimer's drug uptake, may reset price